Abbott Laboratories (ABT) Long-Term Debt Repayments (2010 - 2026)

Abbott Laboratories (ABT) has 15 years of Long-Term Debt Repayments data on file, last reported at $1.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Debt Repayments rose 41.46% year-over-year to $1.4 billion; the trailing twelve-month figure through Mar 2026 stood at $2.9 billion (up 185.9% YoY), and the FY2021 full-year result was $48.0 million, down 96.4% from the prior year.
• Long-Term Debt Repayments advanced to $1.4 billion in Q1 2026, from $501.0 million in the prior quarter.
• In the past five years, Long-Term Debt Repayments ranged from a high of $1.4 billion in Q3 2023 to a low of $1.0 million in Q2 2022.
• A 5-year average of $467.2 million and a median of $18.0 million in 2024 frame the typical range for Long-Term Debt Repayments.
• Across the five-year window, Long-Term Debt Repayments jumped 144400.0% in 2023 and tumbled 99.86% in 2024, its largest moves.
• Tracing ABT's Long-Term Debt Repayments over 5 years: stood at $1.0 million in 2022, then jumped by 144400.0% to $1.4 billion in 2023, then plunged by 99.86% to $2.0 million in 2024, then soared by 24950.0% to $501.0 million in 2025, then jumped by 182.63% to $1.4 billion in 2026.
• Business Quant data shows ABT's Long-Term Debt Repayments at $1.4 billion in Q1 2026, $501.0 million in Q3 2025, and $1.0 million in Q2 2025.